Cyramza (ramucirumab) / Eli Lilly, Innovent Biologics - LARVOL DELTA

Haematological toxicities with targeted drugs in tumors: A systematic review and network meta-analysis of randomized controlled trials (ASH 2025) - "1 patient treated with sorafenib plus chemotherapy was reported to have died as a result of pancytopenia and 1 patient treated with chemotherapy (gemcitabine plus cisplatin) died due to anemia. Our study confirmed that chemotherapy with or without a placebo, one targeted drug with chemotherapy was associated with more severe hematologic toxicities compared with the use of one targeted drug, tepotinib plus gefitinib, tivantinib plus erlotinib. In the targeted drug monotherapy category, for the primary outcome, we found that alectinib and gefitinib had a higher risk of all-grade (grade 1-5) and severe-grade (grade 3-5) anemia, respectively...Ganitumab plus chemotherapy had the highest risk of grade 1-5 anemia and thrombocytopenia. Afatinib plus chemotherapy had the highest risk of grade 3-5 anemia and thrombocytopenia. Ramucirumab plus chemotherapy had the highest risk of grade 1-5 and 3-5 neutropenia. Veliparib plus chemotherapy had the highest risk of grade 1-5 and 3-5..."

Retrospective data • Review • Febrile Neutropenia • Leukopenia • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia

Efficacy and safety of erlotinib and ramucirumab combination therapy in patients harboring EGFR mutations who have previously received osimertinib treatment for non-small cell lung cancer: CS-Lung006 Study (ESMO Asia 2025) - "In patients who received prior treatment with osimertinib, combination therapy with erlotinib and ramucirumab was suggested to be an effective treatment option when osimertinib treatment was discontinued due to toxicity."

Clinical • Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Osimertinib versus erlotinib plus an angiogenesis inhibitor for patients with EGFR-mutated non-small cell lung cancer and pleural effusion (ESMO Asia 2025) - "PFS of MPE (MPE-PFS), PFS, and overall survival (OS) were calculated using Kaplan-Meier curves, and log-rank tests were performed. Of 421 patients, median age was 73 years [range 28-92], 272 (65%) female, performance status 0 or 1 in 334 (79%) cases, adenocarcinoma in 417 (99%) cases, and 373 (89%) received osimertinib, 48 (11%) received erlotinib plus bevacizumab or ramucirumab (E/VEGF group). In patients with EGFR-mutated NSCLC and MPE, osimertinib was shown to be equally effective as erlotinib plus an angiogenesis inhibitor in controlling MPE."

Clinical • Pleural effusion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Clinical efficacy and safety of genexol PM in patients with solid tumours: A retrospective observational study in Indian patients (ESMO Asia 2025) - "Paclitaxel monotherapy was given in 23.7%...Bevacizumab (n=15) was the most used targeted therapy followed by Trastuzumab (n=6) and Ramucirumab (n=5)... These results suggest that Genexol PM cremophor-free formulation is a promising approach in multiple solid malignancies and generally well tolerated among Indian patients."

Observational data • Retrospective data • Breast Cancer • Cervical Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase 2 study. (ASCO-GI 2026) - P2 | "Funded by Taiho , Eli Lilly Clinical Trial Registration Number: NCT04660760 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Combination therapy • Head-to-Head • Metastases • P2 data • Esophageal Adenocarcinoma • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Dose-dependent antitumor activity of HCB101 plus ramucirumab and paclitaxel in previously treated gastric cancer. (ASCO-GI 2026) - P1/2 | "Clinical Trial Registration Number: NCT06771622 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Efficacy and safety of trifluridine/tipiracil plus ramucirumab in advanced gastric cancer as third-line or later treatment: A multicenter phase II study. (ASCO-GI 2026) - "Clinical Trial Registration Number: jRCTs041210105 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. (ASCO-GI 2026) - P | "Funded by HUTCHMED Pharmaceutical Company Clinical Trial Registration Number: NCT07144995 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A multicenter phase II trial of ramucirumab plus irinotecan in patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S-1 therapy: RAMIEL trial (OGSG1901). (ASCO-GI 2026) - "Clinical Trial Registration Number: jRCTs051190071 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • P2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

The primary results of a randomized phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus FTD/TPI for previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma (RETRIEVE study, WJOG 15822G). (ASCO-GI 2026) - "Funded by TAIHO Phamaceutical Co., Ltd. Clinical Trial Registration Number: jRCTs041220120 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Intracranial Atypical Meningioma with Metastases to the Cervical Spine, Pleura and Lungs: A Case Report (SNO 2025) - "At the same hospital, the patient underwent resection, IMRT (60Gy/30Fr), and carboplatin/paclitaxel therapy for the residual tumor in the right pulmonary hilum...Subsequently, two courses of nivolumab/ipilimumab therapy and 14 courses of docetaxel/ramucirumab therapy were administered... Extracranial metastasis of high-grade meningiomas is rare and no standard treatment has been established. We report on this condition, focusing on surgery and GKRS, along with a literature review."

Case report • Clinical • Brain Cancer • Cervical Cancer • Meningioma • Solid Tumor

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Neutropenia • Pediatrics • Soft Tissue Sarcoma

Comparative efficacy and safety of second-line therapies for patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, Front Pharmacol) - "A thorough search was conducted up until 20 February 2025, across the PubMed, Medline, Embase, Cochrane Central, and Web of Science databases to find randomized controlled trials (RCTs) evaluating second-line monotherapies (such as Ramucirumab, Regorafenib, Pembrolizumab, Cabozantinib, and Apatinib) in adults with advanced HCC...Pembrolizumab and Ramucirumab had the most favorable balance of efficacy and tolerability among second-line treatments for advanced HCC and are indicated as optimal therapy alternatives to enhance clinical outcomes. https://www.crd.york.ac.uk/prospero/, identifier CRD420251010308."

Journal • Retrospective data • Review • Hepatocellular Cancer • Oncology • Solid Tumor

A Real-World, Propensity-Matched Analysis of Second-Line FOLFIRI-Ramucirumab Versus Ramucirumab-Paclitaxel in Patients With Advanced Upper Gastrointestinal Cancers. (PubMed, Am J Clin Oncol) - "In a real-world propensity-score matched analysis, no survival difference was noted with the combination of FOLFIRI-Ram compared with Ram-Pac; however, FOLFIRI-Ram was associated with a significantly longer rwTTD. Altogether, these data suggest FOLFIRI-Ram is a potential alternative for second line treatment of UGI cancers."

Journal • Real-world evidence • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pain • Solid Tumor

Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo). (PubMed, Jpn J Clin Oncol) - "FOLFIRI with low-dose irinotecan plus RAM is a feasible second-line treatment in Japanese patients with mCRC."

Journal • P2 data • Cardiovascular • Colorectal Cancer • Hypertension • Neutropenia • Renal Disease • Solid Tumor • EGFR

A Phase II study of Trifluridine/Tipiracil (FTD/TPI) in Combination with Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction adenocarcinomas. (PubMed, Oncologist) - P2 | "The combination of ramucirumab and FTD/TPI demonstrated well-manageable safety profile. Our study did not meet primary endpoint. Ongoing clinical trials will help us understand if ramucirumab plus FTD/TPI is noninferior to ramucirumab/paclitaxel. The trial was registered at www.clinicaltrials.gov (NCT03686488)."

Journal • P2 data • Cardiovascular • Esophageal Cancer • Fatigue • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Hypertension • Neutropenia • Oncology • Pain • Solid Tumor

Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer. (PubMed, JAMA Netw Open) - "The angiogenesis inhibitors indicated for mCRC in France (ie, bevacizumab, aflibercept, ramucirumab, and regorafenib) were considered. No associations were found with either recency or cumulative duration of exposure, regardless of the exposure estimation method. In this case-control study of arterial dissections or aneurysms in patients receiving targeted therapy for mCRC, the lack of association with angiogenesis inhibitor exposure was reassuring, given the established benefits of these drugs, particularly bevacizumab, for this indication."

Journal • Cardiovascular • Colorectal Cancer • Oncology • Solid Tumor • EGFR

Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial. (PubMed, Gastric Cancer) - "Irinotecan-based therapy offers comparable efficacy and tolerability in older and younger patients with refractory AGC."

Journal • Retrospective data • Gastric Cancer • Oncology • Solid Tumor

HCB101, a differentiated SIRpα-fc fusion protein, demonstrates favorable safety and early antitumor activity across solid tumors and lymphomas (ESMO-IO 2025) - P1, P1/2 | "In HCB101-201, combinations showed striking efficacy: in 2L GC, HCB101 with ramucirumab and paclitaxel achieved 100% ORR (6/6) at 5.12–8.0 mg/kg, with regressions up to –78.2%, far exceeding historical benchmarks (∼28%). Safety across combination cohorts was consistent with known SOC toxicities and manageable with standard interventions, with no new immune-related or off-target safety signals attributable to HCB101.Conclusions HCB101 demonstrates a favorable safety profile, durable monotherapy activity in HNSCC and NHL, and striking combination efficacy in GC and TNBC. These data establish HCB101 as a differentiated SIRPα-CD47 therapy with the potential to overcome class limitations and support registrational development across multiple tumor types.Clinical trial identification HCB101-101 (NCT05892718) HCB101-201 (NCT06771622).Legal entity responsible for the study HanchorBio Inc."

Clinical • Breast Cancer • Gastric Cancer • Head and Neck Cancer • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • SIRPA

Determining Candidate D-dimer Thresholds for Lower-extremity Ultrasound in Monitoring Deep Vein Thrombosis in Patients With Gastric Cancer Receiving Ramucirumab. (PubMed, Anticancer Res) - "This exploratory study suggests that a D-dimer level ≥4.4 μg/ml may serve as a candidate indicator for determining the need for lower-extremity ultrasonography in RAM-treated patients with gastric cancer. However, the small number of VTE events and the selective nature of the ROC cohort limit the generalizability. Validation in larger studies is needed."

Journal • Retrospective data • Cardiovascular • Gastric Cancer • Hematological Disorders • Oncology • Solid Tumor • Thrombosis • Venous Thromboembolism

CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - P3 | N=572 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2027 ➔ Sep 2026 | Trial primary completion date: Oct 2026 ➔ May 2026

Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A machine-learning powered liquid biopsy predicts response to paclitaxel plus ramucirumab in advanced gastric cancer: results from the prospective IVY trial. (PubMed, Mol Cancer) - No abstract available

Journal • Liquid biopsy • Gastric Cancer • Oncology • Solid Tumor

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC. (PubMed, JTO Clin Res Rep) - "Patients received RAM (10 mg/kg every 2 wk) plus GEF (250 mg once daily) until disease progression (period 1); patients with disease progression who acquired a T790M mutation received RAM plus osimertinib (80 mg once daily) (period 2). Treatment-emergent T790M rate post progression was 81.3%. RELAY+ revealed a favorable benefit-risk profile for RAM plus GEF in East Asian patients with untreated EGFR-mutated metastatic NSCLC, supporting RAM plus GEF as an alternative first-line treatment option, particularly in those with an L858R mutation."

Journal • Cardiovascular • Hypertension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review. (PubMed, Curr Oncol) - " Docetaxel/ramucirumab is an acceptable regimen for patients progressing on first-line ICI-based therapies. Our results are in concordance with the REVEL study and other retrospective studies of this combination after ICIs."

Journal • Retrospective data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Intracranial Atypical Meningioma with Metastases to the Cervical Spine, Pleura and Lungs: A Case Report (WFNOS 2025) - "At the same hospital, the patient underwent resection, IMRT (60Gy/30Fr), and carboplatin/paclitaxel therapy for the residual tumor in the right pulmonary hilum...Subsequently, two courses of nivolumab/ipilimumab therapy and 14 courses of docetaxel/ramucirumab therapy were administered... Extracranial metastasis of high-grade meningiomas is rare and no standard treatment has been established. We report on this condition, focusing on surgery and GKRS, along with a literature review."

Case report • Clinical • Brain Cancer • Cervical Cancer • Meningioma • Solid Tumor